New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:15 EDTCPRXCatalyst reports successful completion of Type B therapy meeting with FDA
Catalyst Pharmaceutical announced the successful completion of a Type B meeting with the FDA about Firdapse tablets, its lead product being evaluated for the treatment of Lambert Eaton Myasthenic Syndrome, or LEMS. Catalyst provided FDA with an update on the development program for Firdapse, which received Breakthrough Therapy designation from the FDA in August 2013. The company also confirmed with FDA the clinical, nonclinical, and chemistry and manufacturing controls requirements that FDA will require to approve a New Drug Application for Firdapse. This Type B meeting with the FDA was Catalyst's first meeting as the sponsor of the IND for Firdapse. Catalyst will file rolling submissions of the NDA modules as completed in anticipation of receiving a priority review of its NDA for Firdapse. The Company provided a briefing package to the FDA that described all completed, in-progress, and planned preclinical studies, clinical studies, and drug manufacturing activities. This package included summaries of 54 preclinical studies, six clinical studies, and information related to drug manufacturing. The FDA concurred that the Company's completed, in-progress, and planned development activities represented a nearly complete package of information that would be needed for a complete NDA.
News For CPRX From The Last 14 Days
Check below for free stories on CPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:02 EDTCPRXCatalyst Pharmaceutical, BioMarin in amended license agreement
Catalyst Pharmaceutical (CPRX) disclosed in a regulatory filing that on April 15, effective as of April 8, the company and BioMarin Pharmaceutical (BMRN) entered into Amendment No. 1 to License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the company and BioMarin. The company intends to submit a FOIA Confidential Treatment Request to the SEC pursuant to Rule 24b-2 under the SEC Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
April 14, 2014
10:02 EDTCPRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:14 EDTCPRXCatalyst Pharmaceutical initiated with an Overweight at Piper Jaffray
Target $4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use